Patents Examined by Sandra Dillahunt
  • Patent number: 9950035
    Abstract: Methods for making non-immunogenic anti-inflammatory cytokine compositions, comprising (a) obtaining a liquid comprising cytokine producing cells from a mammalian donor; (b) contacting the liquid with a solid extraction material to generate a composition rich in interleukin-1 receptor antagonist; and performing one or both of (i) removing cells from the composition and (ii) freezing the composition. The compositions comprise two or more of IL1-ra, sTNF-R1, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-?1, and sIL-1RII, Compositions may also contain white blood cells and platelets.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: April 24, 2018
    Assignee: Biomet Biologics, LLC
    Inventors: Jeffrey R. Binder, Joel C. Higgins, Michael D. Leach, Krista O'Shaughnessey, Jennifer E. Woodell-May
  • Patent number: 9879062
    Abstract: Embodiments of the invention are described, including materials and methods for making molecules and materials that have a specific binding domain of a PlGF2. Embodiments include, for instance, medicaments, biomaterials, biomolecules, molecular fusions, and vaccines.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: January 30, 2018
    Assignee: Ecole Polytechnique Federale De Lausanne
    Inventors: Jeffrey A. Hubbell, Mikael Martino, Priscilla S. Maithili Briquez
  • Patent number: 9845456
    Abstract: A composition for deriving the maturation of dendritic cells includes complex cytokines generated by the simulation, the expression of which is induced on EBV-infected B cells. The dendritic cell maturation process, which conventionally takes approximately 7 days, can be shortened to 2 days, thereby producing dendritic cells in a more economically advantageous and effective manner.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: December 19, 2017
    Assignee: INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Dae Young Hur, Ga Bin Park, Yeong Seok Kim, Hyun Kyung Lee, Dae Jin Kim
  • Patent number: 9834612
    Abstract: The present invention provides anti-TCblR antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer, tumors and other proliferative diseases and disorders.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: December 5, 2017
    Assignee: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
    Inventors: Edward V. Quadros, Jeffrey M. Sequeira
  • Patent number: 9815895
    Abstract: The present invention relates to a method of reducing the numbers of eosinophils in a human subject comprising administration to a subject an IL-5R binding molecule that comprises (a) a region that specifically binds to the IL-5R and (b) an immunoglobulin Fc region. In a specific embodiment, a method of the invention reduces the number of eosinophils in blood, bone marrow, gastrointestinal tract (e.g. esophagus, stomach, small intestine and colon), or lung.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: November 14, 2017
    Assignees: BIOWA, INC., ASTRAZENECA AB
    Inventors: Masamichi Koike, George L. Spitalny, Alistair Wheeler, Barbara White
  • Patent number: 9814767
    Abstract: This document provides methods and materials for generating CD8+ T cells having the ability to recognize cancer cells expressing a HER2/neu polypeptide. For example, methods and materials for using a polypeptide consisting of an SLAFLPESFD amino acid sequence in vivo or in vitro to generate CD8+ T cells having the ability to recognize and lyse cancer cells expressing a HER2/neu polypeptide are provided.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: November 14, 2017
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Keith L. Knutson, Andrea M. Henle
  • Patent number: 9801942
    Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: October 31, 2017
    Assignee: Coherus Biosciences, Inc.
    Inventors: Mark Manning, Brian Murphy
  • Patent number: 9803009
    Abstract: Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-?), e.g., human TNF-?, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: October 31, 2017
    Assignee: AbbVie Inc.
    Inventors: Chung-Ming Hsieh, Lorenzo Benatuil, Yuliya Kutskova, John Memmott, Jennifer Perez, Suju Zhong, Carrie Goodreau, Anca Clabbers
  • Patent number: 9795671
    Abstract: The present invention relates to inhibitors of VAP-1 and their use as medicaments in treating fibrotic conditions. Furthermore, the present invention relates to a method of diagnosing a fibrotic condition on the basis of elevated level of soluble VAP-1 or SSAO activity in a bodily fluid, and to a kit for use in said diagnostic method.
    Type: Grant
    Filed: September 7, 2010
    Date of Patent: October 24, 2017
    Assignees: BIOTIE THERAPIES CORP., THE UNIVERSITY OF BIRMINGHAM
    Inventors: Christopher Weston, Lee Charles Claridge, David Adams, David Smith, Nina Westerlund, Max Ole Valdemar Westerlund, Marjo Pihlavisto, Thua Österman, Elina Ainomaija Antikainen
  • Patent number: 9758558
    Abstract: A biodegradable hydrogel has been made based on high concentrations of whey protein isolate (WPI). WPI gels of different compositions were fabricated by thermally inducing gelation of high-concentration suspensions of protein, and characterized for compressive strength and modulus, hydration swelling and drying properties, mechanical behavior change due to polysaccharide additives, and intrinsic pore network structure. The gels were shown to be compatible with bone cells and could be used as bone tissue scaffolds. In addition, WPI fibers were produced by electrospinning. Several additives could be incorporated into the WPI gels, including structural additives, growth factors, amino acids, etc. The WPI hydrogels can be made with glycerol to increase flexibility and stability.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: September 12, 2017
    Assignee: Board of Supervisors of Louisiana State University And Agriculture and Mechanical College
    Inventors: James E. Henry, Mia Dvora
  • Patent number: 9739784
    Abstract: Provided herein are methods and kits for evaluating potential for invasiveness, metastasis, or recurrence of an epithelial cell cancer. In the methods the expression profile of giant obscurins is detected in a tissue sample of tumor cells or suspected tumor cells and assessed for giant obscuring expression level and distribution therein. Decreased levels or altered distribution of giant obscurins in the cells compared to a control non-invasive standard or to a sample taken at a different point in time is indicative of increased potential of at least one of the invasiveness, metastasis, or recurrence of the epithelial cell cancer. The kit comprises a detection reagent suitable for detecting the presence and distribution of giant obscurins or an amount of the gene product(s) encoding giant obscurins in cells of a tissue sample and instructions for using the detection reagent.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: August 22, 2017
    Assignees: UNIVERSITY OF MARYLAND, BA, JOHNS HOPKINS UNIVERSITY
    Inventors: Aikaterini Kontrogianni-Konstantopoulos, Konstantinos Konstantopoulos, Marey Shriver, Nicole Perry
  • Patent number: 9701751
    Abstract: Antibodies to human GITR are provided, as well as uses thereof, e.g., in treatment of proliferative and immune disorders.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: July 11, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Xiao Min Schebye, Grigori P. Ermakov, Douglas J. Hodges, Leonard G. Presta
  • Patent number: 9670262
    Abstract: The present invention relates to modified SAK gene having amino acid SEQ ID 2. The present invention further relates to process for cloning and expressing modified SAK gene fusion protein which imparts improved stability to the heterologous protein of interest. Further the invention relates to process of purification of recombinant heterologous proteins from bacterial inclusion bodies using modified SAK.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: June 6, 2017
    Assignee: LUPIN LIMITED
    Inventors: Shardul Salunkhe, Bhaskarjyoti Prasad, Praveen Muneshwar, Anjali Apte Deshpande, Sriram Padmanabhan
  • Patent number: 9657073
    Abstract: A protease resistant polypeptide includes an amino acid sequence that has a sequence identity at least 80% homologous to about 10 to 80 consecutive amino acids of SEQ ID NO:1.
    Type: Grant
    Filed: September 1, 2011
    Date of Patent: May 23, 2017
    Assignee: Case Western Reserve University
    Inventors: Clark Distelhorst, Yiping Rong
  • Patent number: 9649374
    Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 006-H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.
    Type: Grant
    Filed: November 18, 2010
    Date of Patent: May 16, 2017
    Assignee: Bayer Intellectual Property GMBH
    Inventors: Christiane Otto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder, Andrea Eicker, Andreas Wilmen
  • Patent number: 9629910
    Abstract: Described herein are methods for the treatment of cancer (e.g. melanoma, lung cancer, or other cancers). The methods involve administrating to a subject in need thereof an agonist of the IL-9 receptor (e.g. IL-9), e.g. an agent that binds and activates the IL-9 receptor, or an agent that increases IL-9 expression in the subject (e.g. administration of TH9 cells that express IL-9, or administration of an inhibitor of ROR).
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: April 25, 2017
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Thomas S. Kupper, Rahul Purwar
  • Patent number: 9625445
    Abstract: Methods for detection and diagnosis of Sjögren's Syndrome in a subject, determining the stage or progression of Sjögren's Syndrome in a subject, determining the effectiveness of a treatment for Sjögren's Syndrome, and selecting a subject for treatment for Sjögren's Syndrome are disclosed. The methods typically include measuring the level of one or more Sjögren's Syndrome biomarkers in a biological sample obtained from a subject. Biomarkers for Sjögren's Syndrome include, but are not limited to, GADD153 and Del-1.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: April 18, 2017
    Assignee: Augusta University Research Institute, Inc.
    Inventors: Babak Baban, Mahmood Mozaffari, Rafik Abdelsayed, Jun Yao Liu
  • Patent number: 9605038
    Abstract: The present invention relates to a fusion peptide comprising dhFas-1 domain and MMP substrate and use thereof. More specifically, the present invention relates to a fusion peptide, comprising a) a dhFas-1 domain which is the fourth fas-1 domain of ?ig-h3 lacking H1 and H2 regions; b) a MMP (Matrix metalloproteinase) substrate; and c) a peptide comprising RGD motif and an use thereof for preventing and treating inflammatory disease. The fusion peptide of the present invention inhibits expension of rheumatoid arthritis by adhesion and migration of sinoviocytes and may be used for preventing or treating inflammatory disease by inhibiting infiltration of immune cells.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: March 28, 2017
    Assignee: Kyungpook National University Industry—Academic Cooperation Foundation
    Inventors: Young Mo Kang, In San Kim, Jin Hee Kang, Keum Hee Sa
  • Patent number: 9598487
    Abstract: The invention provides antibodies that are modified to reduce aggregration propensity, and methods of producing such antibodies. The present invention also provides particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: March 21, 2017
    Assignee: ESBATech, an Alcon Biomedical Unit LLC
    Inventors: Leonardo Jose Borras, David Urech
  • Patent number: 9556243
    Abstract: Apparatus and methods for generating a solution rich in interleukin-1 receptor antagonist from a tissue comprising cytokine-producing cells. The apparatus can include a filter used with a separation system. The separation system can include a float.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: January 31, 2017
    Assignee: Biomet Biologies, LLC
    Inventors: Michael D. Leach, Jennifer E. Woodell-May, Joel C. Higgins, Krista O'Shaughnessey